计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
产品介绍:
BAW2881 (NVP-BAW2881)是一种新型的VEGFR酪氨酸激酶抑制剂。在1.0-4.3 nM浓度下能有效地抑制VEGFR1-3;在45-72 nM的浓度下,抑制PDGFRβ, c-Kit和RET (c-RET)。
Information
BAW2881 (NVP-BAW2881) is a novelvascular endothelial growth factor (VEGF) receptor tyrosine-kinaseinhibitor that potently inhibits VEGFR1-3 at 1.0-4.3 nanomolar (nM) concentrations and inhibits PDGFRβ, c-Kit, and RET (c-RET) at 45-72 nM concentrations.
Targets
hVEGFR2 (Cell-free assay); C-Raf-1 (Cell-free assay); B-RAFV599E (Cell-free assay); c-Abl (Cell-free assay); mVEGF2 (Cell-free assay) 16390,9 nM; 24 nM; 76 nM; 99 nM; 165 nM
In vitro
In vitro studies demonstrated that NVP-BAW2881 inhibited proliferation, migration, and tube formation of human umbilical vein endothelial cells and lymphatic endothelial cells.
In vivo
NVP-BAW2881 targets the tyrosine kinase domain of murine, porcine, and human VEGFR2. It can be administered both orally and topically, but has not been tested in humans. In vivo studies in VEGF-A transgenic mice showed that oral and topical administration of NVP-BAW2881 strongly reduced psoriasis-like inflammation in ear skin. Histologically, skin lesions in treated mice showed reduced infiltration by leukocytes, reduced epidermal hyperproliferation, normalization of epidermal keratinocyte differentiation, and fewer vascular abnormalities. Vessels in treated mice were smaller in size and fewer in number. In comparison to control mice, treated mice showed significant improvement in ear swelling, skin inflammation, lymph node enlargement, and skin erythema. Though both modes of administration were effective, systemic administration of NVP-BAW2881 was more potent than topical administration. Topical NVP-BAW2881 also effectively reduced VEGF-A-induced vascular permeability in the skin of mice and domestic pigs.
Cell Research(from reference)
Cell lines:Human dermal lymphatic endothelial cells(LECs), human umbilical vein endothelial cells(HUVECs)
Concentrations:1 nmol/L to 1 mol/L
Incubation Time:72 h
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 苯类化合物 |
| 类(Class) | 萘 |
| 亚类(Subclass) | 萘甲酸及其衍生物 |
| 中间层级节点(Intermediate Tree Nodes) | 萘甲酰胺 |
| 直接上位类(Direct Parent) | 萘-1-甲酰苯胺 |
| 其他上位类(Alternative Parents) | 芳香族苯胺 二芳醚 三氟甲基苯 酚醚 氨基嘧啶及其衍生物 杂芳族化合物 仲羧酸酰胺 氨基酸及其衍生物 氮杂环化合物 伯胺 有机氟化物 有机氧化物 碳氢化合物衍生物 烷基氟化物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 氟化烷基 - 烷基溴化物 - 氨基酸 - 氨基酸或其衍生物 - 氨基吡啶 - 芳香族苯胺 - 芳香族杂多环化合物 - 氮杂环 - 羧酰胺基 - 羧酸衍生物 - 二芳基醚 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - 单环苯基基团 - 萘-1-甲酰苯胺 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氟化物 - 有机卤化物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 苯酚醚 - 初级胺 - 嘧啶 - 醛基 - 三氟甲基苯 |
| 描述(Description) | 该化合物属于有机化合物中的萘-1-甲酰胺类。这类化合物是萘-1-甲酰胺,其中甲酰胺基团被苯胺取代。 |
| 外部描述符(External Descriptors) | 暂无 |
| IC50 | hVEGFR3, IC50: 420 nM |
|---|---|
| ALogP | 4.56 |
| hba_count | 4 |
| HBD Count | 2 |
| Rotatable Bond | 5 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
H302: 吞食有害
H315: 引起皮肤刺激
H319: 引起严重眼睛刺激
H335: 可能引起呼吸道刺激
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾
P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。